Icagen 10-Q 20 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 20, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Icagen, Inc.
Entity Central Index Key	1,518,520
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,393,107

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 1,666,329	$ 2,763,596
Accounts receivable, net	1,782,820	1,739,895
Inventory	79,170	73,885
Prepaid expenses and other current assets	158,354	213,367
Total Current Assets	3,686,673	4,790,743
Non-Current Assets
Intangibles, net	7,314,579	7,427,071
Plant and equipment, net	1,763,750	2,181,753
Deposits	238,987	238,987
Total Non-Current Assets	9,317,316	9,847,811
Total Assets	13,003,989	14,638,554
Current Liabilities
Accounts payable	2,617,275	1,471,645
Other payables and accrued expenses	3,299,522	2,440,442
Legal settlement accrual	10,000	493,333
Loans payable	54,484	139,394
Deferred revenue	219,827	219,828
Deferred purchase consideration	200,000	206,458
Dividends payable	59,540
Total Current Liabilities	6,460,648	4,971,100
Non-Current Liabilities
Deferred purchase consideration, net	8,282,202	8,232,664
Loans payable	45,094	71,296
Convertible loans payable, net	6,555,804	5,861,794
Derivative liability	6,601,201	4,168,964
Total Non-Current Liabilities	21,484,301	18,334,718
Total Liabilities	27,944,949	23,305,818
Commitment and contingencies
Stockholders' Deficit
Preferred stock, value
Common stock, $0.001 par value; 50,000,000 shares authorized, 6,720,107 shares issued and 6,393,107 outstanding as of June 30, 2018 and December 31, 2017.	6,392	6,392
Additional paid-in-capital	26,102,573	25,084,252
Treasury stock, at cost (327,000 shares of common stock as of June 30\, 2018 and December 31, 2017.	(237)	(237)
Accumulated deficit	(41,050,288)	(33,757,671)
Total Stockholder's Deficit	(14,940,960)	(8,667,264)
Total Liabilities and Stockholders' Deficit	13,003,989	14,638,554
Series C Preferred Stock
Stockholders' Deficit
Preferred stock, value	$ 600

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock undesignated and unissued shares	5,457,144	5,457,144
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,720,107	6,720,107
Common stock, shares outstanding	6,393,107	6,393,107
Treasury stock, shares	327,000	327,000
Series A Preferred Stock
Preferred stock designated shares	400,000	400,000
Series B Preferred stock
Preferred stock designated shares	3,000,000	3,000,000
Series C Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	599,991
Preferred stock, shares outstanding	599,991
Preferred stock designated shares	1,142,856	1,142,856
Liquidation preference	$ 3,149,953

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statements of Operations [Abstract]
Sales	$ 4,375,969	$ 5,774,547	$ 7,457,118	$ 11,594,497
Cost of sales	2,871,930	3,084,736	5,521,244	6,021,346
Gross profit	1,504,039	2,689,811	1,935,874	5,573,151
Operating expenses:
Selling, general and administrative expenses	2,648,323	3,814,546	5,640,644	6,912,820
Depreciation	368,274	458,174	825,730	842,905
Amortization	56,246	56,246	112,492	112,492
Total Operating expenses	3,072,843	4,328,966	6,578,866	7,868,217
Operating loss	(1,568,804)	(1,639,155)	(4,642,992)	(2,295,066)
Other income (expense)
Other income		500,000	6,384	500,226
Interest expense	(791,210)	(854,838)	(1,550,932)	(1,004,879)
Derivative liability movement	(1,140,623)	77,719	(1,045,537)	77,719
Total other expense	(1,923,833)	(277,119)	(2,590,085)	(426,934)
Net loss before income tax	(3,500,637)	(1,916,274)	(7,233,077)	(2,722,000)
Income tax
Net loss	(3,500,637)	(1,916,274)	(7,233,077)	(2,722,000)
Preferred stock dividend	(59,540)		(59,540)
Net loss available to common stock holders	$ (3,560,177)	$ (1,916,274)	$ (7,292,617)	$ (2,722,000)
Net Loss Per Share - Basic and Diluted	$ (0.56)	$ (0.30)	$ (1.14)	$ (0.43)
Weighted Average Number of Shares Outstanding - Basic and Diluted	6,393,107	6,393,107	6,393,107	6,393,107

Unaudited Condensed Consolidat5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,233,077)	$ (2,722,000)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation expense	825,730	842,905
Amortization expense	112,492	112,492
Stock based compensation charge	305,620	315,192
Amortization of debt discount	694,010	535,282
Derivative liability movements	1,045,537	(77,719)
Deferred purchase consideration unearned by vendor		(500,000)
Imputed interest on acquisition of Icagen assets	149,538	292,517
Changes in operating assets and liabilities
Accounts receivable	(42,925)	(705,538)
Inventory	(5,285)
Prepaid expenses and other current assets	55,013	190,454
Accounts payable	1,145,630	(289,379)
Deferred subsidy		(4,800,000)
Deferred revenues	(1)	(417,591)
Other payables and accrued expenses	369,290	(579,612)
CASH USED IN OPERATING ACTIVITIES	(2,578,428)	(7,802,997)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment of deferred purchase consideration	(100,000)	(50,000)
Purchase of plant and equipment	(407,727)	(555,125)
Purchase of intangibles		(153,164)
Proceeds on assets held for resale		20,381
NET CASH USED IN INVESTING ACTIVITIES	(507,727)	(737,908)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible loan		9,600,000
Proceeds from bridge notes		1,500,000
Repayment of bridge notes		(1,500,000)
Repayment of Asset financing	(111,112)	(201,257)
Proceeds from the sale of Series C Convertible Preferred Stock	2,100,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,988,888	9,398,743
NET (DECREASE) INCREASE IN CASH	(1,097,267)	857,838
Cash at the beginning of the period	2,763,596	4,938,948
CAST AT END OF PERIOD	1,666,329	5,796,786
CASH PAID FOR INTEREST AND TAXES:
Cash paid for income taxes
Cash paid for interest	689,385	172,253
NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of warrants issued concurrently with Series C Preferred Stock	1,386,699
Fair value of warrants issued concurrent with bridge notes		330,353
Discount on convertible debt and warrants issued concurrent with debt		$ 4,518,278

General Information

General Information	6 Months Ended
	Jun. 30, 2018
General Information [Abstract]
GENERAL INFORMATION	1. GENERAL INFORMATION Icagen, Inc. (“the Company”, “we”, “us”, “our”) is a Delaware corporation. The principal office of the Company is in Durham, North Carolina. The Company was incorporated in November 2003.

Accounting Policies and Estimat

Accounting Policies and Estimates	6 Months Ended
	Jun. 30, 2018
Accounting Policies and Estimates [Abstract]
ACCOUNTING POLICIES AND ESTIMATES	2. ACCOUNTING POLICIES AND ESTIMATES General The (a) unaudited condensed consolidated balance sheets as of June 30, 2018, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2017, which have been derived from audited consolidated financial statements, and (b) the unaudited interim condensed consolidated statements of operations and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months and six months ended June 30, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on April 17, 2018. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements. All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows: Icagen, Inc. - Parent Company Icagen Corp - Wholly owned subsidiary Icagen-T Inc. - Wholly owned subsidiary Caldera Discovery, Inc. - Wholly owned subsidiary XRPro Sciences, Inc. - Wholly owned subsidiary The preparation of these unaudited condensed consolidated financial statements in accordance with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company continually evaluates its estimates, including those related to bad debts and recovery of long-lived assets. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to the Company’s reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, the valuation of certain assets and intangibles acquired from a subsidiary of Pfizer, Inc., Icagen, and assumptions used in assessing impairment of long-term assets, the assumptions used in determining percentage of completion on its long-term contracts, and the assumptions used to calculate fair value of warrants and options granted, in addition to assumptions used to calculate the value of the derivative liability. Concentrations of credit risk The Company maintains cash with major financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) provides insurance coverage for deposits of corporations, the current limit of coverage is $250,000. As a result of this coverage the Company has cash balances of $1,233,033 that are not covered by the FDIC as of June 30, 2018. Concentration of major customers The Company derives its revenues from commercial pharmaceutical and biotechnology companies from Government research contracts and Government grants. The Company derived 71.0% of its services revenue from four major customers during the six months ended June 30, 2018. During the six months ended June 30, 2017, the Company derived 71.3% of its revenue from three major customers. The Company continues to expand its customer base of major customers and partners. Three months ended Six months ended June 30, June 30, June 30, June 30, Services revenue $ 4,375,969 $ 3,179,958 $ 7,457,118 $ 6,473,753 Subsidy revenue - 2,400,000 - 4,800,000 Government grants - 194,589 - 320,744 $ 4,375,969 $ 5,774,547 $ 7,457,118 $ 11,594,497 Accounts receivable and other receivables The Company has a policy of reserving for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. As a basis for accurately estimating the likelihood of collection of its accounts receivable, the Company considers a number of factors when determining reserves for uncollectable accounts. The Company believes that it uses a reasonably reliable methodology to estimate the collectability of its accounts receivable. The Company reviews its allowances for doubtful accounts on a regular basis. The Company also considers whether the historical economic conditions are comparable to current economic conditions. If the financial condition of its customers or other parties that it has business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The balance of the receivables provision as at June 30, 2018 and December 31, 2017 was $0 and $0, respectively. The amount charged to bad debt provision for the three and six months ended June 30, 2018 and 2017 was $0 and $0, respectively. Inventory Inventory consists of laboratory consumables. The Company values inventory at the lower of cost or net realizable value applied on a first-in, first-out basis. The Company identifies and writes down its excess and obsolete inventory to net realizable value based on usage forecasts, order volume and inventory aging. Revenue recognition The Company’s revenue recognition policy is consistent with the requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue. The Company has analyzed its revenue transactions pursuant to ASC 606, Revenue, and it has no material impact as a result of the transition from ASC 605 to 606. The Company’s revenues are recognized when control of the promised services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services, as defined below. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: i. identify the contract with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to performance obligations in the contract; and v recognize revenue as the performance obligation is satisfied. Revenue sources consist of commercial contracts, deferred subsidy revenue and government grants and contracts. The Company enters into fixed fee commercial development contracts that are associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed. In the prior year, the Company had received certain deferred subsidy revenue which was utilized to support its operations, maintain the facilities that it operates in and continue the employment of certain employees to provide, if needed, resources to certain of its customers. This deferred subsidy revenue was amortized over a straight-line basis to match the expected expenses to be incurred over the period July 15, 2016 to December 31, 2017. The Company received and will receive certain revenue in advance of services delivered. This revenue is deferred and only recognized when services have been performed in terms of master services agreements entered into with customers, together with their associated Statements of Work. The Company accounts for its long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract. The Company generally uses the cost-to-cost measure of progress for all its long-term contracts, unless it believes another measure will produce a more reliable result. The Company believes that the cost-to-cost measure is the best and most reliable performance indicator of progress on its long-term contracts as all its contract estimates are based on costs that it expects to incur in performing its long-term contracts and it has not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred. When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined. Net income (loss) per Share Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period. Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). Fair value of financial instruments The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the balance sheets for cash, accounts receivable, other current assets, other assets, accounts payable, accrued liabilities, and notes payable, approximate fair value due to the relatively short period to maturity for these instruments. The Company identified derivative liabilities relating to convertible debt instruments and certain variably priced warrants which are required to be presented on the balance sheets at fair value in accordance with the accounting guidance. ASC 825-10 “ Financial Instruments Beneficial conversion feature of convertible notes payable The Company accounts for convertible notes payable in accordance with guidelines established by the FASB ASC Topic 470-20, “Debt with Conversion and Other Options”. The beneficial conversion feature of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a beneficial conversion feature related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. The beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. The beneficial conversion feature of a convertible note is measured by first allocating a portion of the note’s proceeds to any warrants, if applicable, as a discount on the carrying amount of the convertible on a relative fair value basis. The discounted face value is then used to measure the effective conversion price of the note. The effective conversion price and the market price of the Company’s common stock are used to calculate the intrinsic value of the conversion feature. The intrinsic value is recorded in the financial statements as a debt discount from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to amortization of debt discount on the Company’s consolidated statement of operations. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the preferred shares transaction and the effective conversion price embedded in the preferred shares. Derivative Liabilities The Company has derivative financial instruments as of June 30, 2018 and December 31, 2017. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re- measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Black-Scholes option valuation model was used to estimate the fair value of the conversion options. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time, of other comparative securities, equal to the weighted average life of the options. Conversion options related to debt instruments are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument using effective interest method. Conversion options related to equity instruments are recorded as a deemed dividend at the grant date of the equity instrument. Research and Development The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred. Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life. The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three and six months ended June 30, 2018 was $676,583 and $1,535,778 and for the three and six months ended June 30, 2017 was $791,732 and $1,486,620, respectively. Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, its board members and members of the immediate families of principal owners of the Company. Parties are also considered related parties if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. Recent accounting pronouncements In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The impact of this ASU on the Company’s financial statements is not expected to be material. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements. The amendments in this Update provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption consistent with preparers’ requests. The amendments in this Update provide lessors with a practical expedient, by class of underlying asset, to not separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606) and both of the following are met: 1. The timing and pattern of transfer of the non-lease component(s) and associated lease component are the same. 2. The lease component, if accounted for separately, would be classified as an operating lease. The amendments in this Update related to separating components of a contract affect the amendments in Update 2016-02, which are not yet effective but can be early adopted. The Company is currently considering the impact this ASU will have on its financial statements. Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2018
Going Concern [Abstract]
GOING CONCERN	3. GOING CONCERN As shown in the accompanying unaudited condensed consolidated financial statements, the Company incurred a net loss of $(7,233,077) for the six months ended June 30, 2018 and $(6,110,434) for the year ended December 31, 2017, respectively. As of the six months ended June 30, 2018, and the year ended December 31, 2017 the Company had accumulated deficits of $41,050,288 and $33,757,671, respectively. The Company’s working capital deficit increased from $(180,357) to $(2,773,975). The Company’s working capital is insufficient to meet its short-term cash requirements and fund any future operating losses. These operating losses create an uncertainty about the Company’s ability to continue as a going concern. The Company’s plan, through the acquisition of the assets of Sanofi and Icagen and the continued promotion of its services to existing and potential customers is to generate sufficient revenues to cover its anticipated expenses. The Company closed its first and second tranche of a preferred stock equity raise on April 4, 2018 and May 30, 2018, raising an aggregate of $2,100,000, subsequent to June 30, 2018, the Company closed a third tranche of a preferred stock raise on July 11, 2018, raising an additional $400,000. Subsequent to June 30, on August 13, 2018, we closed the first tranche of fifty units of our note and warrant offering of a maximum of one hundred fifty units, each unit consisting of a $10,000 note and a warrant exercisable for 1,500 shares of common stock at an exercise price of $3.50 per share, raising an additional $500,000. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, the management of the Company believes that the revenue to be generated from operations together with additional issuances of equity or other potential financing will provide the necessary funding for the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is economically dependent upon future capital or financing to fund ongoing operations.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2018
Inventory [Abstract]
INVENTORY	4. INVENTORY Inventory represents the value of certain consumables utilized in the Company’s biological screening processes. These consumables are purchased in bulk and expensed as they are utilized.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2018
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS June 30, December 31, Prepaid insurance $ 37,072 $ 75,774 Prepaid maintenance 119,511 129,260 Prepaid rent - 2,500 Prepaid subscriptions 1,771 5,833 $ 158,354 $ 213,367

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2018
Intangible Assets [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS Intangible assets consist of the following: June 30, December 31, Cost Amortization and Impairment Net book value Net book value Cell lines $ 5,153,664 $ - $ 5,153,664 $ 5,153,664 Discovery platform 1,450,500 (435,150 ) 1,015,350 1,087,875 Trade names and trademarks 637,500 - 637,500 637,500 Assembled workforce 282,500 (84,750 ) 197,750 211,875 Patents 972,000 (661,685 ) 310,315 336,157 $ 8,496,164 $ (1,181,585 ) $ 7,314,579 $ 7,427,071 The aggregate amortization expense charged to operations was $56,246 for each of the three months ended June 30, 2018 and 2017, and $112,492 for each of the six months ended June 30, 2018 and 2017, respectively. Amortization expense for future periods is summarized as follows: Amount 2018 $ 112,492 2019 224,984 2020 224,984 2021 224,984 2022 and thereafter 735,971 Total $ 1,523,415

Plant and Equipment

Plant and Equipment	6 Months Ended
	Jun. 30, 2018
Plant and Equipment [Abstract]
PLANT AND EQUIPMENT	7. PLANT AND EQUIPMENT Plant and equipment consists of the following: June 30, December 31, Cost Amortization and Impairment Net book value Net book value Laboratory equipment $ 2,495,965 $ (1,214,464 ) $ 1,281,501 $ 1,396,617 Computer software 1,671,192 (1,246,969 ) 424,223 716,860 Computer equipment 94,276 (52,337 ) 41,939 43,816 Leasehold improvements 38,974 (22,887 ) 16,087 24,460 $ 4,300,407 $ (2,536,657 ) $ 1,763,750 $ 2,181,753 Depreciation expense for the three months ended June 30, 2018 and 2017 was $368,274 and $458,174, respectively, and $825,730 and $842,905 for the six months ended June 30, 2018 and 2017, respectively.

Other Payable and Accrued Expen

Other Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2018
Other Payable and Accrued Expenses [Abstract]
OTHER PAYABLE AND ACCRUED EXPENSES	8. OTHER PAYABLE AND ACCRUED EXPENSES Other payables and accrued expenses consist of the following: June 30, December 31, Bonus and vacation accrual $ 2,373,987 $ 1,871,488 Payroll liabilities 61,628 44,858 Severance cost accrual 76,355 262,966 Interest accrual 118,768 108,333 Advances from shareholders 300,000 - Other 368,784 152,797 $ 3,299,522 $ 2,440,442 The Company accrues for vacation pay and bonus accruals in anticipation of making payments based on the achievement of predetermined goals. The Company received $300,000 from certain shareholders, designated as Series C Preferred units, the Securities Purchase Agreements related to these proceeds have not been concluded yet, upon execution of the Securities Purchase Agreements, the Series C Preferred units will be issued to the shareholders.

Legal Settlement Liabilities

Legal Settlement Liabilities	6 Months Ended
	Jun. 30, 2018
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
LEGAL SETTLEMENT LIABILITIES	9. LEGAL SETTLEMENT LIABILITIES The legal settlement liabilities consists of the following: June 30, December 31, Settlement liability accruals Dentons dispute $ - $ 400,000 Eisenschenk matter - 83,333 Other 10,000 10,000 10,000 493,333 Disclosed as follows: Short-term portion 10,000 493,333 $ 10,000 $ 493,333 The Company has settled all outstanding legal matters with the remaining $10,000 representing a contingency accrual.

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2018
Deferred Revenue [Abstract]
DEFERRED REVENUE	10. DEFERRED REVENUE Deferred revenue represents payments received in advance from customers in terms of master service agreements entered into with them. Revenue is recognized as and when the work is performed.

Deferred Purchase Consideration

Deferred Purchase Consideration	6 Months Ended
	Jun. 30, 2018
Deferred Purchase Consideration [Abstract]
DEFERRED PURCHASE CONSIDERATION	11. DEFERRED PURCHASE CONSIDERATION In terms of the Icagen asset purchase agreement entered into on July 1, 2015, with a subsidiary of Pfizer, Inc, now known as Pfizer Research (NC), Inc., the Company has the following deferred purchase price obligations: ● commencing May 30, 2017, the Company is obligated to pay additional purchase price consideration calculated (“Earn Out Payment”) at the greater of (i) 10% (ten percent) of gross revenues per quarter (exclusive of revenue paid by Sanofi to Icagen-T) and (ii) $250,000 per quarter up to an aggregate maximum of $10,000,000 (the “Maximum Earn Out Payment”), subject to the next paragraph. These earn out payments are payable quarterly, 60 days after the completion of each calendar quarter. There are no indications that the Company will not meet the maximum earn out payment. The Company amended its agreement with Pfizer Research (NC), Inc. (the “Second Amendment”), whereby the Company, at its option, may defer payment of any amount exceeding $50,000 of the minimum additional purchase price consideration of $250,000 per quarter until March 31, 2019 such that the Company is only required to pay $50,000 per quarter for the quarters ending March 2017 to December 2018. Deferred purchase consideration bears interest at a rate of 12.5% per annum, which interest is payable quarterly. The deferred purchase consideration in terms of this agreement is payable, together with the deferred purchase consideration for the quarter ended March 31, 2019, as one lump sum. The Second Amendment also provides that if there is an Insolvency Event (as such term is defined in the Second Amendment) prior to the time that Pfizer Research (NC), Inc. has received the Maximum Earn Out Payment, then upon such Insolvency Event, the full amount of any Earn Out Shortfall (the difference between the Maximum Earn Out Payment and the amount of all Earn Out Payments paid to date) shall be due and payable without further notice, demand or presentment for payment. ● The $500,000 deferred purchase consideration due on July 1, 2017, was not earned by Pfizer due to Pfizer not meeting its $4,000,000 revenue target. This liability of $500,000 was reversed as other income during the year ended December 31, 2017. Deferred purchase consideration is disclosed as follows: June 30, December 31, Deferred purchase consideration Opening balance $ 9,856,458 $ 10,500,000 Reversal of unearned purchase consideration - (500,000 ) Interest due on deferred purchase consideration 50,978 25,578 Repayment (147,001 ) (169,120 ) Closing balance 9,760,435 9,856,458 Present value discount on future payments Opening balance (1,417,336 ) (1,712,689 ) Imputed interest expense 149,538 300,511 Fair value adjustments - (5,158 ) Closing balance (1,267,798 ) (1,417,336 ) Deferred purchase consideration, net 8,492,636 8,439,122 Disclosed as follows: Short-term portion 200,000 206,458 Interest disclosed under other payables 10,434 - Long-term portion 8,282,202 8,232,664 Deferred purchase consideration, net $ 8,492,636 $ 8,439,122

Loans Payable

Loans Payable	6 Months Ended
	Jun. 30, 2018
Loans Payable [Abstract]
LOANS PAYABLE	12. LOANS PAYABLE Loans payable consist of the following: June 30, December 31, Asset purchase arrangements $ 99,578 $ 210,690 99,578 210,690 Disclosed as follows: Short-term portion 54,484 139,394 Long-term portion 45,094 71,296 $ 99,578 $ 210,690 Future principal payments under loans payable are as follows: Amount Within 1 year $ 54,484 Within 1 - 2 years 45,094 $ 99,578 Asset Purchase arrangements The Company acquired laboratory equipment on August 11, 2017 for a purchase consideration of $59,320 in terms of a deferred purchase arrangement whereby a deposit of $5,932 was paid and twenty-four monthly installments of $2,472 will be paid commencing on September 11, 2017. The installments bear interest at an effective rate of 10.33% per annum. The Company owed $35,208 as of June 30, 2018. The Company acquired laboratory software during September 2017 for a purchase consideration of $98,446 in terms of a deferred purchase arrangement whereby a deposit of $10,546 was paid and the balance payable in thirty five monthly installments of $2,750 each, which commenced on September 30, 2017. The installments bear interest at an effective rate of 6.15% per annum. The Company owed $64,370 as of June 30, 2018.

Convertible Debt

Convertible Debt	6 Months Ended
	Jun. 30, 2018
Convertible Debt [Abstract]
CONVERTIBLE DEBT	13. CONVERTIBLE DEBT On May 15, 2017, the Company, and its wholly owned subsidiary, Icagen-T, Inc. (“Icagen-T”), entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which (i) the Company issued to the Purchaser a three year Senior Secured Convertible Note (“Company Note”), maturing on May 15, 2020, bearing interest at the rate of 13% per annum (which interest rate increases to 18% per annum upon the occurrence of an event of default, as defined in the Company Note), in the aggregate principal amount of $2,000,000 for cash proceeds of $1,920,000 after an original issue discount of 4% or $80,000, before deal related expenses; and (ii) Icagen-T issued to the Purchaser a three year Senior Secured Convertible Note (“Icagen-T Note”), maturing on May 15, 2020, bearing interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000 for cash proceeds of $7,680,000 after an original issue discount of 4% or $320,000, before transaction related expenses. The Company Note and the Icagen-T Note (collectively, the “Convertible Notes”) are each convertible into shares of common stock at a conversion price of $3.50 per share. The Purchaser may elect to have the Company and/or Icagen-T redeem the Convertible Notes upon the occurrence of certain events, including upon a certain Events of Default (as defined in the Notes). The Convertible Notes contain customary Events of Default. In addition, any time after issuance, so long as no Event of Default has occurred and/or is continuing, each of the Company and Icagen-T, has the right to redeem all or part of each Convertible Note then outstanding, with a minimum prepayment amount of $500,000, at any time upon five (5) business days’ notice to the Purchaser by paying an amount in cash equal to: a range between 101% and 103% of the Conversion Amount being redeemed if paid in full and if an Event of Default has occurred and is continuing the Purchaser has the right to require the Company to redeem the Conversion Amount for an amount of cash equal to a range between 116% and 118% of the Conversion Amount being redeemed. The “Conversion Amount” is defined as the sum of (a) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made, (b) all accrued and unpaid Interest with respect to such portion of such principal, (c) all accrued and unpaid late charges with respect to such portion of such principal and such Interest, if any, and (d) all other amounts due thereunder. The Notes contain certain covenants, such as restrictions on the incurrence of indebtedness, the existence of liens, the payment of restricted payments, redemptions, the payment of cash dividends and the transfer of assets. If the Company fails to timely deliver the shares underlying the Notes, it will be subject to certain buy-in provisions. In addition, pursuant to the Securities Purchase Agreement, the Company and Icagen-T have agreed to provide certain registration rights with respect to the Conversion Shares underlying the Icagen-T Note and, if Rule 144 under the Securities Act, is unavailable, for the Warrant Shares and Conversion Shares underlying the Company Note. In addition, pursuant to the Convertible Notes, neither the Company nor Icagen-T shall enter into or be party to a Fundamental Transaction (as defined in the Convertible Notes) unless (i) the Successor Entity (as defined in the Convertible Notes) assumes in writing all of the obligations of the Company, Icagen-T and each Subsidiary under the Convertible Notes and the other Transaction Documents (as defined in the Securities Purchase Agreement) pursuant to written agreements in form and substance reasonably satisfactory to the Purchaser and approved by the Purchaser prior to such Fundamental Transaction, including agreements to deliver to the Purchaser in exchange for the Convertible Note and securities of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Notes, including, without limitation, having principal amounts, interest rates and late charges equal to the payment rights and amounts, principal amounts then outstanding, the interest rates and late charges in the Notes as well as having the conversion rights, redemption rights, rankings, Events of Default the same as in the Notes and satisfactory to the Purchaser, and (ii) the Successor Entity is a trading issuer whose common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, and is quoted and/or listed for trading on a Qualifying Market. The Convertible Notes also contain certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization and, sales of securities below the conversion price of the Notes. In addition, subject to limited exceptions, a holder of the Company Note and Icagen-T Note will not have the right to convert any portion of such note if such holder, together with its affiliates, would beneficially own in excess of the Beneficial Ownership Limitation. A holder of the Company Note and Icagen-T Note may adjust the Beneficial Ownership Limitation upon not less than 61 days’ prior notice to the Parent, provided that such Beneficial Ownership Limitation in no event shall exceed 4.99%. The Company used the proceeds from the Company Note to repay the $1,500,000 aggregate principal amount of the 8% bridge notes issued in April 2017 and all accrued but unpaid interest thereon and to pay an amount of $500,000 owed by the Company pursuant to the terms of the Dentons settlement agreement, Icagen-T has been using the net proceeds from the purchase price paid to Icagen-T for its general corporate and working capital purposes; provided, however, neither the Company nor Icagen-T may use any of their respective net proceeds for (a) the repayment of any indebtedness other than Permitted Indebtedness (as defined in the Convertible Notes), (b) the redemption or repurchase of any securities of the Company, Icagen-T or their Subsidiaries, or (c) except for the payments pursuant to the Settlement Agreement, the settlement of any outstanding litigation; provided, further, Icagen-T will not use any of such proceeds in violation of its arrangements with Sanofi. In connection with the Convertible Notes, the Company issued a warrant (the “Purchaser Warrant”) to purchase initially up to 857,143 shares of Common Stock at an initial exercise price of $3.50 per share, subject to applicable adjustments. The Purchaser Warrant expires on May 15, 2022. In addition, subject to limited exceptions, a holder of the Purchaser Warrant will not have the right to exercise any portion of the Purchaser Warrant if such holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to its conversion (the “Beneficial Ownership Limitation”). A holder of the Purchaser Warrant may adjust the Beneficial Ownership Limitation upon not less than 61 days’ prior notice to the Company, provided that such Beneficial Ownership Limitation in no event shall exceed 9.99%. The Purchaser Warrant also contain certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization and, issuances of securities at prices below the conversion price or similar transactions. If, at the time a holder exercises the Purchaser Warrant, there is no effective registration statement available for an issuance of the shares underlying the Purchaser Warrant to the holder, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of the Company’s Common Stock determined according to a formula set forth in the Purchaser Warrant. If the Company fails to timely deliver the shares underlying the Purchaser Warrants, it will be subject to certain buy-in provisions. The Purchaser Warrant also provides that the Company will not enter into or be party to a Fundamental Transaction (as defined in the Purchaser Warrant) unless (i) the Successor Entity (as defined in the Purchaser Warrant) assumes in writing all of the obligations of the Company under the Purchaser Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) pursuant to written agreements in form and substance satisfactory to the Purchaser, including agreements to deliver to the Purchaser in exchange for the Purchaser Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Purchaser Warrant; (ii) the Parent or the Successor Entity (as the case may be) agrees at the election of the Company or the Successor Entity (as the case may be) to purchase the Purchaser Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value (as defined in the Purchaser Warrant); or (iii) the Purchaser, at its election, requires the Company or the Successor Entity (as the case may be) to purchase the Purchaser Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value. The Company Note is secured by a security interest in all of the existing and future assets of the Company and the domestic subsidiaries, other than Icagen-T, including a pledge of all of the capital stock of each of the Domestic Subsidiaries, other than Icagen-T, subject to existing security interests, for the benefit of the Purchaser, to secure the Company obligations under the Company Note, as evidenced by (i) a security and pledge agreement, and (ii) a guaranty executed by each Domestic Subsidiary, other than Icagen-T, pursuant to which the domestic subsidiaries, other than Icagen-T, guaranteed all obligations of the Company under the Transaction Documents. The Icagen-T Note is secured by a security interest in all of the existing and future assets of the Company, Icagen-T and the other Domestic Subsidiaries, including a pledge of all of the capital stock of each of the Domestic Subsidiaries, other than Icagen-T, subject to existing security interests, for the benefit of the Purchaser, to secure Icagen-T’s obligations under the Icagen-T Note, as evidenced by (i) a security and pledge agreement, and (ii) a guaranty executed by the Company and each Domestic Subsidiary, other than Icagen-T, pursuant to which the Company and the Domestic Subsidiaries, other than Icagen-T, guaranteed all of the obligations of Icagen-T under the Transaction Documents. In addition, the Company and Icagen-T entered into a Subordinated Deed of Trust, Assignment of Rents, Fixture Filing and Security Agreement with the trustee named therein and the Purchaser as beneficiary, securing all of Icagen-T’s obligations to the Purchaser by a senior priority security interest in the Property/Facilities, which is subordinated only to a Deed of Trust entered into with Sanofi. Upon an Event of Default, the Purchaser may, among other things, collect or take possession of the Company collateral or Icagen-T collateral, as the case may be, proceed with the foreclosure of the security interest in the collateral or sell, lease or dispose of the collateral. Each of the Subsidiaries has also guaranteed all of the Company’s obligations under the Company Note pursuant to the terms of the Company Guaranty and the Icagen-T Guaranty. The transactions contemplated by the Securities Purchase Agreement closed and funded on May 15, 2017. The movement on convertible debt is as follows: June 30, December 31, Convertible debt Opening balance $ 10,000,000 $ - Convertible debt issued - 10,000,000 Closing balance 10,000,000 10,000,000 Debt discount Opening balance (4,138,206 ) - Original issue discount - (400,000 ) Fair value of warrants and beneficial conversion feature of notes - (4,518,277 ) Amortization of debt discount 694,010 780,071 Closing balance (3,444,196 ) (4,138,206 ) Convertible debt, net 6,555,804 5,861,794 Disclosed as follows: Short-term portion - - Long-term portion 6,555,804 5,861,794 Convertible debt, net $ 6,555,804 $ 5,861,794

Derivative Liability

Derivative Liability	6 Months Ended
	Jun. 30, 2018
Derivative Liability [Abstract]
DERIVATIVE LIABILITY	14. DERIVATIVE LIABILITY The Convertible Notes, together with the Purchaser Warrants issued to the note holders, disclosed in note 13 above, have variable priced conversion rights which may adjust whenever new securities are issued at prices lower than the current conversion and exercise price of the Convertible Notes and Purchaser Warrants issued to note holders. This gives rise to a derivative financial liability, which was initially valued upon the issue of the Convertible Notes and Purchaser Warrants using a Black-Scholes valuation model. The Beneficial conversion feature of the Convertible Notes was valued at $3,069,649 and the Purchaser Warrants issued in connection with the Convertible Notes were valued at $1,448,629. On April 2, 2018 and May 30, 2018, the Company closed on the first tranche and second tranche of the Series C Preferred units, discussed in note 15 below. Each Preferred Series C unit includes warrants exercisable over 28,571 shares of common stock at an initial exercise price of $3.50 per share subject to anti-dilution pricing adjustments. The anti-dilution pricing adjustments give rise to a derivative financial liability which was initially valued using a Black Scholes valuation model at $1,386,699. The value of the derivative liability is re-assessed periodically and a mark-to-market adjustment, if applicable will be recorded in the statement of operations. The value of the derivative liability was re-assessed on June 30, 2018 and a mark-to-market loss of $1,045,537 was debited to the statement of operations for the six months ended June 30, 2018. The following assumptions were used in the Black-Scholes valuation model. Six months ended June 30, 2018 Calculated stock price $ 3.50 Risk free interest rate 2.39 to 2.78% Valuation period 1.88 to 7 years expected volatility of underlying stock 44.6 to 68.0% Expected dividend rate 0% The movements in the derivative financial liability is as follows: June 30, December 31, Opening balance $ 4,168,965 $ - Derivative liability on beneficial conversion feature of convertible debt and warrants issued to note holders - 4,518,278 Derivative liability on the fair value of series C Preferred stock warrants issued 1,386,699 - Mark-to-market adjustment 1,045,537 (349,313 ) Closing balance $ 6,601,201 $ 4,168,965

Series C Preferred Stock

Series C Preferred Stock	6 Months Ended
	Jun. 30, 2018
Series C Preferred Stock [Abstract]
SERIES C PREFERRED STOCK	15. SERIES C PREFERRED STOCK Series C Preferred Stock consists of 1,142,856 authorized shares of $0.001 each, of which 599,991 and 0 shares are issued and outstanding as of June 30, 2018 and December 31, 2017, respectively. On April 3, 2018, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware establishing the Series C Convertible Preferred Stock which entitles each holder of Series C Preferred Stock to a cumulative dividend at the rate of 12.0% per annum, payable quarterly in arrears. The Company has offered on a best efforts basis up to a maximum of forty (40) units and a minimum of ten (10) units, at a purchase price of $100,000 per unit, each unit consisting of 28,571 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”) and a seven year Warrant to acquire 28,571 shares of the Company’s common stock, par value, $0.001 per share, at an exercise price of $3.50 per share. On April 4, 2018, the Company closed on its first tranche of 20 Series C Preferred units for gross proceeds of $2,000,000 with a member of its Board of Directors. On May 30, 2018, the Company closed on its second tranche of 1 Series C Preferred unit for gross proceeds of $100,000 with a member of its Board of Directors. The Series C Preferred Stock ranks senior to the shares of the Company’s common stock, and any other class or series of stock issued by us with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of its affairs. Holders of Series C Preferred Stock are entitled to a cumulative dividend at the rate of 12.0% per annum, as set forth in the Certificate of Designation of Series C Convertible Preferred Stock. The Series C Preferred Stock is convertible at the option of the holders at any time into such number of shares of common stock as shall be equal to the $3.50 plus any accrued and unpaid dividends on such share of Series C Preferred Stock (the “Accreted Value”) divided by the conversion price, which initially is $3.50 per share, subject to certain customary anti-dilution adjustments. In addition, the Series C Preferred Stock automatically converts into shares of the Company’s common stock based upon the then effective conversion price upon the (i) closing of a sale of shares of common stock to the public in a Qualifying Public Offering (as defined below) or a reverse merger into a publicly reporting company that has its common stock listed or quoted and traded on a Trading Market (as such term is defined in the Certificate of Designation) or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least seventy-five percent (75%) of the outstanding shares of Series C Preferred Stock (the “Requisite Holders”) (the time of such closing or the date and time specified of the event specified in such vote or written consent is referred to herein as the “Mandatory Conversion Date”). A “Qualifying Public Offering” is defined as the first firm commitment underwritten public offering by the Company on or following the initial issuance date of the Series C Preferred in which shares of common stock are sold for its account solely for cash to the public resulting in proceeds to it and/or its subsidiary, Icagen-T, Inc. of no less than $8,000,000 (after deduction only of underwriter discounts and commissions) and where the shares of common stock registered under the Securities Act of 1933, as amended, and sold in such public offering are simultaneously listed and commence trading on a Trading Market (as such term is defined in the Certificate of Designation) In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series C Preferred Stock shall be entitled to a preference on liquidation equal to $5.25 per share of Series C Preferred Stock plus all accrued and unpaid dividends. Each holder of Series C Preferred Stock shall have the right to cast the number of votes equal to three times the number of shares into which the Series C Preferred Stock is convertible and the Series C holders as a group, shall have the right to elect one director on the Company’s Board of Directors. The Company cannot take the following actions without the approval of the Requisite Holders and the consent of its Board of Directors, including the Series C Preferred Stock director: (i) liquidate, dissolve or wind up its business, (ii) amend its Certificate of Incorporation or Bylaws, (iii) create any new class of stock unless it ranks junior to the Series C Preferred Stock with respect to dividends and liquidation, (iv) amend or alter any class of stock pari passu with the Series C Preferred Stock to make it senior with respect to dividends and liquidation, (v) purchase or redeem any other shares of its stock, or (vi) increase the size of its Board of Directors. Upon the occurrence of a Cash Liquidity Event, the holders of the Series C Preferred Stock can require the Company to redeem their shares for Series C Preferred Stock for a price per share equal to $5.25 subject to adjustments. In addition, the Company has the right to redeem the shares at any time for a price per share equal to $5.25 subject to adjustments. A “Cash Liquidity Event” is defined as the closing of any sale, lease or licensing transaction relating to a single asset or multiple assets other than in the ordinary course of the Company’s business, including, but not limited to a sale of a building, sale of biological assets or other upfront payments, resulting in aggregate gross proceeds received by us at closing or closings in a transaction or transactions during any twelve (12) month period in excess of $40,000,000. During the three and six months ended June 30, 2018, the Company has accrued dividends of $59,540 on Series C Preferred Stock.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2018
Common Stock [Abstract]
COMMON STOCK	16. COMMON STOCK Common stock consists of 50,000,000 authorized shares of $0.001 each, 6,720,107 shares issued and 6,393,107 shares outstanding as of June 30, 2018 and December 31, 2017.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2018
Warrants [Abstract]
WARRANTS	17. WARRANTS As part of the Series C Preferred Units, the Company issued Warrants to the Purchaser at an initial exercise price of $3.50 per share (subject to applicable adjustments) (the “ Exercise Price In addition, subject to limited exceptions, a holder of the Warrant will not have the right to exercise any portion of the Warrant if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to such exercise. A holder of the Warrant may adjust this limitation upon not less than 61 days’ prior notice to the Company, provided that such limitation in no event shall exceed 9.99%. The Warrants also contain certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization and issuances of securities at prices below the conversion price or similar transactions. If, at the time a holder exercises its Warrant, there is no effective registration statement available for an issuance of the shares underlying the Warrant to the holder, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Warrant. If the Company fails to timely deliver the shares underlying the Warrant, it will be subject to certain buy-in provisions. The Warrant also provides that the Company will not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity (as defined in the Warrant) assumes in writing all of the obligations of the Parent under the Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) pursuant to written agreements in form and substance satisfactory to the Purchaser, including agreements to deliver to the Purchaser in exchange for the Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrant; (ii) the Company or the Successor Entity (as the case may be) agrees at the election of the Company or the Successor Entity (as the case may be) to purchase the Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value (as defined in the Warrant); or (iii) the Purchaser, at its election, requires the Company or the Successor Entity (as the case may be) to purchase the Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value. On April 4, 2018, the Company closed on its first tranche of 20 Series C Preferred units for gross proceeds of $2,000,000 with a member of its Board of Directors, resulting in warrants exercisable over 571,420 shares of common stock at an initial exercise price of $3.50 per share. On May 30, 2018, the Company closed on its second tranche of 1 Series C Preferred unit for gross proceeds of $100,000 with a member of its Board of Directors, resulting in warrants exercisable over 28,571 shares of common stock at an initial exercise price of $3.50 per share. A summary of the Company’s warrant activity during the period January 1, 2017 to June 30, 2018 is as follows: No. of Exercise price per share Weighted average exercise Outstanding January 1, 2017 2,147,641 $3.50 to $11.40 $ 3.57 Granted 1,107,143 3.50 3.50 Forfeited/cancelled (75,000 ) 4.20 4.20 Exercised - - - Outstanding December 31, 2017 3,179,784 $3.50 to $4.20 3.50 Granted 599,991 - 3.50 Forfeited/cancelled (75,000 ) 4.20 4.20 Exercised - - - Outstanding June 30, 2018 3,704,775 $3.50 to $4.20 $ 3.51 The following table summarizes warrants outstanding and exercisable as of June 30, 2018: Warrants outstanding Warrants exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $ 3.50 3,561,374 3.27 3,561,374 $ 3.85 143,401 2.00 143,401 3,704,775 3.22 $ 3.51 3,704,775 $ 3.51

Stock Options

Stock Options	6 Months Ended
	Jun. 30, 2018
Stock Options [Abstract]
STOCK OPTIONS	18. STOCK OPTIONS A summary of all of the option activity during the period January 1, 2017 to June 30, 2018 is as follows: No. of Exercise price per share Weighted average exercise Outstanding January 1, 2017 1,333,291 $0.40 to $11.42 $ 3.59 Granted 120,000 3.50 3.50 Forfeited/cancelled (33,332 ) 3.50 3.50 Exercised - - - Outstanding December 31, 2017 1,419,959 $0.40 to $11.42 3.59 Granted - - Forfeited/cancelled (37,014 ) 3.50 3.50 Exercised - - - Outstanding June 30 , 2018 1,382,945 $0.40 to $11.42 $ 3.59 The following tables summarize information about stock options outstanding as of June 30, 2018: Options outstanding Options exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $ 0.40 15,000 4.58 15,000 $ 3.00 312,500 5.45 312,500 $ 3.50 902,154 8.17 527,697 $ 4.00 8,791 2.28 8,791 $ 5.00 128,500 3.24 128,500 $ 11.42 16,000 3.92 16,000 1,382,945 6.22 $ 3.59 1,008,488 $ 3.63 No options were granted during the six months ended June 30, 2018. As of June 30, 2018, there were unvested options to purchase 374,457 shares of common stock. Total expected unrecognized compensation cost related to such unvested options is $791,156 which is expected to be recognized over a period of 36 months. Stock option based compensation expense totaled $151,712 and $165,282 for the three months ended June 30, 2018 and 2017, respectively, and $305,620 and $315,192 for the six months ended June 30, 2018 and 2017 respectively. Stock options outstanding as of June 30, 2018 as disclosed in the above table, have an intrinsic value of $202,750.

Interest Expense

Interest Expense	6 Months Ended
	Jun. 30, 2018
Interest Expenses [Abstract]
INTEREST EXPENSE	19. INTEREST EXPENSE Interest expense consists of the following: Three months ended Three months ended Six months ended Six months ended Imputed interest $ (74,769 ) $ (143,205 ) $ (149,538 ) $ (292,517 ) Debt discount (358,625 ) (535,282 ) (694,010 ) (535,282 ) Interest expense (357,816 ) (174,928 ) (706,845 ) (175,267 ) Other (1,423 ) (539 ) (1,813 ) $ (791,210 ) $ (854,838 ) $ (1,550,932 ) $ (1,004,879 )

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2018
Net Loss Per Common Share [Abstract]
NET LOSS PER COMMON SHARE	20. NET LOSS PER COMMON SHARE For the three and six months ended June 30, 2018 and 2017, respectively, the following convertible securities, options and warrants were excluded from the computation of diluted net loss per shares as the result of the computation was anti-dilutive: Three months and Three months and Stock options 1,382,945 1,453,291 Warrants 3,704,775 3,254,784 Convertible securities 3,457,134 - 8,544,854 4,708,075

Related Party Transaction

Related Party Transaction	6 Months Ended
	Jun. 30, 2018
Related Party Transaction [Abstract]
RELATED PARTY TRANSACTION	21. RELATED PARTY TRANSACTION Timothy Tyson On April 4, 2018, the Company entered into a Securities Purchase Agreement whereby Mr. Tyson acquired twenty (20) Series C Preferred Stock units for $100,000 each, each unit consisting of 28,571 Series C Preferred shares and a seven year warrant exercisable over 28,571 shares of common stock, at an exercise price of $3.50 per share. Mr. Tyson acquired a total of 571,420 Series C Preferred shares and warrants exercisable over 571,420 shares of common stock. Clive Kabatznik On May 30, 2018, the Company entered into a Securities Purchase Agreement whereby Mr. Kabatznik acquired one (1) Series C Preferred Stock unit for $100,000 each, each unit consisting of 28,571 Series C Preferred shares and a seven year warrant exercisable over 28,571 shares of common stock, at an exercise price of $3.50 per share. Mr. Kabatznik acquired a total of 28,571 Series C Preferred shares and warrants exercisable over 28,571 shares of common stock. Michael Taglich On May 30, 2018, Mr. M. Taglich advanced the Company $150,000, to be designated as Series C Preferred units. No Securities Purchase Agreement has been entered into as yet, therefore the Company has reflected the advance as a payable, refer note 8 above. Robert Taglich On May 30, 2018, Mr. R. Taglich advanced the Company $150,000, to be designated as Series C Preferred units. No Securities Purchase Agreement has been entered into as yet, therefore the Company has reflected the advance as a payable, refer note 8 above.

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2018
Operating Leases [Abstract]
OPERATING LEASES	22. OPERATING LEASES The Company entered into an asset purchase agreement with Icagen, Inc., a subsidiary of Pfizer, Inc., whereby certain assets were acquired from Icagen, Inc., the agreement included the sub-letting of premises located at Research Triangle Park, Durham, North Carolina. The lease terminates on April 30, 2019. The rental expense for the six months ended June 30, 2018 amounted to $98,915. Future annual minimum payments required under operating lease obligations as of June 30, 2018, are as follows: Amount 2018 $ 96,653 2019 66,649 Total $ 163,601

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	23. COMMITMENTS AND CONTINGENCIES As a result of the agreements that the Company entered into with Pfizer and Sanofi, the Company is obligated; (i) to continue to retain certain employees at its Icagen-T facility until July 15, 2018, which it estimates will require additional compensation of $400,000 at its Icagen-T facility; (ii) make additional payments in terms of the Asset Purchase and Collaboration Agreement that it entered into on June 26, 2015 with Pfizer including beginning in 2017, a quarterly earn out payment (the “Earn Out Payment”) of 10% of revenue earned during the quarter, with a minimum payment of $250,000 per quarter, up to a maximum aggregate payment of $10,000,000, such minimum being reduced to $50,000 for the quarters ending March 2017 to December 2018 and the difference between $250,000 or the quarterly amount paid and the actual calculation of deferred purchase consideration at 10% of gross revenue per quarter is being deferred and paid as one lump sum with the payment being made the quarter ended March 31, 2019, bearing interest at 12.5% per annum, which interest is payable quarterly; (iii) make minimum lease payments in terms of a sub-lease agreement entered into with Pfizer for the period July l, 2015 to April 30, 2019 with annual escalations of 3.5%, estimated to be $163,601. On May 15, 2017, the Company, and its wholly owned subsidiary, Icagen-T, entered into a Securities Purchase Agreement with an institutional investor (the “Purchaser”), On June 19, 2017, the Company entered into a four-year employment agreement with Douglas Krafte, Ph.D., pursuant to which Dr. Krafte is entitled to an annual base salary of $285,000 and will be eligible for annual discretionary performance bonus payments of up to 35% of his base salary payable in cash, which bonus, if any, will be awarded in the sole and absolute discretion of the Company’s board of directors and the compensation committee of the board of directors. Dr. Krafte continues to be engaged as the Company’s Chief Scientific Officer.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	24. SUBSEQUENT EVENTS Private Placement The Company has offered on a best efforts basis up to a maximum of forty (40) units and a minimum of ten (10) units, at a purchase price of $100,000 per unit, each unit consisting of 28,571 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”) and a seven year Warrant to acquire 28,571 shares of the Company’s common stock, par value, $0.001 per share, at an exercise price of $3.50 per share. On July 13, 2018, the Company closed the third tranche of the Offering and entered into a securities purchase agreement with one accredited investor that is a trust of which a member of its Board of Directors is the trustee, pursuant to which the Company offered and sold an aggregate of four (4) Units. The sale of the four (4) Units resulted in gross offering proceeds of $400,000. On August 13, 2018, the Company closed the first tranche of its note and warrant offering of a maximum of one hundred fifty (150) units and entered into a Securities Purchase Agreement (the “Purchase Agreement”) with four accredited investors, which included a trust of which one member of the Company’s Board of Directors is the trustee and two other members of the Board of Directors (the “Purchasers”), pursuant to which the Company issued to the Purchasers an aggregate of fifty (50) units, at a purchase price of $10,000 per unit, each unit consisting of: (i) the Company’s 10% Subordinated Promissory Note in the principal amount of $10,000 due on the earlier of: (x) the date that is twelve (12) months after its issue date or (y) the Company’s receipt of the proceeds of funding from its next collaboration/partnership (the “Note”) and (ii) a five year warrant to purchase 1,500 shares of common stock of the Company for each $10,000 Note investment of the Company at an exercise price of $3.50 per share (the “Warrant”). An aggregate of $500,000 in principal amount of Notes and Warrants to purchase an aggregate of 75,000 shares of common stock were sold at the closing. The gross cash proceeds to the Company from the sale of the fifty (50) units was $500,000. The Notes and all obligations thereunder are subordinated in right of payment in all respects to that certain Senior Secured Convertible Note, dated May 10, 2017, in the principal amount of $2,000,000 issued by the Company to GPB Debt Holdings II, LLC (“GPB”) and the obligations of the Company as a guarantor of the amounts owed under that certain Senior Secured Convertible Note, dated May 10, 2017, in the principal amount of $8,000,000 issued by the Company’s subsidiary, Icagen-T, Inc. to of GPB. As part of the Units, the Company issued the Warrants to the Purchasers to purchase shares of the Company’s common stock at an initial exercise price of $3.50 per share (subject to applicable adjustments) (the “Exercise Price”). The Warrants expire five (5) years after the issuance date. The Company has evaluated subsequent events through the date the unaudited condensed consolidated financial statements were available to be issued and has concluded that no such events or transactions took place that would require disclosure herein.

Accounting Policies and Estim30

Accounting Policies and Estimates (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies and Estimates [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements. All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Consolidation	Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows: Icagen, Inc. - Parent Company Icagen Corp - Wholly owned subsidiary Icagen-T Inc. - Wholly owned subsidiary Caldera Discovery, Inc. - Wholly owned subsidiary XRPro Sciences, Inc. - Wholly owned subsidiary The preparation of these unaudited condensed consolidated financial statements in accordance with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company continually evaluates its estimates, including those related to bad debts and recovery of long-lived assets. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to the Company’s reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, the valuation of certain assets and intangibles acquired from a subsidiary of Pfizer, Inc., Icagen, and assumptions used in assessing impairment of long-term assets, the assumptions used in determining percentage of completion on its long-term contracts, and the assumptions used to calculate fair value of warrants and options granted, in addition to assumptions used to calculate the value of the derivative liability.
Concentrations of credit risk	Concentrations of credit risk The Company maintains cash with major financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) provides insurance coverage for deposits of corporations, the current limit of coverage is $250,000. As a result of this coverage the Company has cash balances of $1,233,033 that are not covered by the FDIC as of June 30, 2018.
Concentration of major customers	Concentration of major customers The Company derives its revenues from commercial pharmaceutical and biotechnology companies from Government research contracts and Government grants. The Company derived 71.0% of its services revenue from four major customers during the six months ended June 30, 2018. During the six months ended June 30, 2017, the Company derived 71.3% of its revenue from three major customers. The Company continues to expand its customer base of major customers and partners. Three months ended Six months ended June 30, June 30, June 30, June 30, Services revenue $ 4,375,969 $ 3,179,958 $ 7,457,118 $ 6,473,753 Subsidy revenue - 2,400,000 - 4,800,000 Government grants - 194,589 - 320,744 $ 4,375,969 $ 5,774,547 $ 7,457,118 $ 11,594,497
Accounts receivable and other receivables	Accounts receivable and other receivables The Company has a policy of reserving for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. As a basis for accurately estimating the likelihood of collection of its accounts receivable, the Company considers a number of factors when determining reserves for uncollectable accounts. The Company believes that it uses a reasonably reliable methodology to estimate the collectability of its accounts receivable. The Company reviews its allowances for doubtful accounts on a regular basis. The Company also considers whether the historical economic conditions are comparable to current economic conditions. If the financial condition of its customers or other parties that it has business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The balance of the receivables provision as at June 30, 2018 and December 31, 2017 was $0 and $0, respectively. The amount charged to bad debt provision for the three and six months ended June 30, 2018 and 2017 was $0 and $0, respectively.
Inventory	Inventory Inventory consists of laboratory consumables. The Company values inventory at the lower of cost or net realizable value applied on a first-in, first-out basis. The Company identifies and writes down its excess and obsolete inventory to net realizable value based on usage forecasts, order volume and inventory aging.
Revenue recognition	Revenue recognition The Company’s revenue recognition policy is consistent with the requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue. The Company has analyzed its revenue transactions pursuant to ASC 606, Revenue, and it has no material impact as a result of the transition from ASC 605 to 606. The Company’s revenues are recognized when control of the promised services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services, as defined below. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: i. identify the contract with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to performance obligations in the contract; and v recognize revenue as the performance obligation is satisfied. Revenue sources consist of commercial contracts, deferred subsidy revenue and government grants and contracts. The Company enters into fixed fee commercial development contracts that are associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed. In the prior year, the Company had received certain deferred subsidy revenue which was utilized to support its operations, maintain the facilities that it operates in and continue the employment of certain employees to provide, if needed, resources to certain of its customers. This deferred subsidy revenue was amortized over a straight-line basis to match the expected expenses to be incurred over the period July 15, 2016 to December 31, 2017. The Company received and will receive certain revenue in advance of services delivered. This revenue is deferred and only recognized when services have been performed in terms of master services agreements entered into with customers, together with their associated Statements of Work. The Company accounts for its long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract. The Company generally uses the cost-to-cost measure of progress for all its long-term contracts, unless it believes another measure will produce a more reliable result. The Company believes that the cost-to-cost measure is the best and most reliable performance indicator of progress on its long-term contracts as all its contract estimates are based on costs that it expects to incur in performing its long-term contracts and it has not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred. When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.
Net income (loss) per Share	Net income (loss) per Share Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period. Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).
Fair value of financial instruments	Fair value of financial instruments The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows: Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the balance sheets for cash, accounts receivable, other current assets, other assets, accounts payable, accrued liabilities, and notes payable, approximate fair value due to the relatively short period to maturity for these instruments. The Company identified derivative liabilities relating to convertible debt instruments and certain variably priced warrants which are required to be presented on the balance sheets at fair value in accordance with the accounting guidance. ASC 825-10 “ Financial Instruments
Beneficial conversion feature of convertible notes payable	Beneficial conversion feature of convertible notes payable The Company accounts for convertible notes payable in accordance with guidelines established by the FASB ASC Topic 470-20, “Debt with Conversion and Other Options”. The beneficial conversion feature of a convertible note is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a beneficial conversion feature related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. The beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. The beneficial conversion feature of a convertible note is measured by first allocating a portion of the note’s proceeds to any warrants, if applicable, as a discount on the carrying amount of the convertible on a relative fair value basis. The discounted face value is then used to measure the effective conversion price of the note. The effective conversion price and the market price of the Company’s common stock are used to calculate the intrinsic value of the conversion feature. The intrinsic value is recorded in the financial statements as a debt discount from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to amortization of debt discount on the Company’s consolidated statement of operations. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the preferred shares transaction and the effective conversion price embedded in the preferred shares.
Derivative Liabilities	Derivative Liabilities The Company has derivative financial instruments as of June 30, 2018 and December 31, 2017. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re- measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Black-Scholes option valuation model was used to estimate the fair value of the conversion options. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time, of other comparative securities, equal to the weighted average life of the options. Conversion options related to debt instruments are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument using effective interest method. Conversion options related to equity instruments are recorded as a deemed dividend at the grant date of the equity instrument.
Research and Development	Research and Development The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred. Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life. The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three and six months ended June 30, 2018 was $676,583 and $1,535,778 and for the three and six months ended June 30, 2017 was $791,732 and $1,486,620, respectively.
Related parties	Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, its board members and members of the immediate families of principal owners of the Company. Parties are also considered related parties if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.
Recent accounting pronouncements	Recent accounting pronouncements In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The impact of this ASU on the Company’s financial statements is not expected to be material. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements. The amendments in this Update provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption consistent with preparers’ requests. The amendments in this Update provide lessors with a practical expedient, by class of underlying asset, to not separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606) and both of the following are met: 1. The timing and pattern of transfer of the non-lease component(s) and associated lease component are the same. 2. The lease component, if accounted for separately, would be classified as an operating lease. The amendments in this Update related to separating components of a contract affect the amendments in Update 2016-02, which are not yet effective but can be early adopted. The Company is currently considering the impact this ASU will have on its financial statements. Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Accounting Policies and Estim31

Accounting Policies and Estimates (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies and Estimates [Abstract]
Schedule of total revenues by major customer type	Three months ended Six months ended June 30, June 30, June 30, June 30, Services revenue $ 4,375,969 $ 3,179,958 $ 7,457,118 $ 6,473,753 Subsidy revenue - 2,400,000 - 4,800,000 Government grants - 194,589 - 320,744 $ 4,375,969 $ 5,774,547 $ 7,457,118 $ 11,594,497

Prepaid Expenses and Other Cu32

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of prepaid expenses and other current assets	June 30, December 31, Prepaid insurance $ 37,072 $ 75,774 Prepaid maintenance 119,511 129,260 Prepaid rent - 2,500 Prepaid subscriptions 1,771 5,833 $ 158,354 $ 213,367

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Intangible Assets [Abstract]
Schedule of intangible assets	June 30, December 31, Cost Amortization and Impairment Net book value Net book value Cell lines $ 5,153,664 $ - $ 5,153,664 $ 5,153,664 Discovery platform 1,450,500 (435,150 ) 1,015,350 1,087,875 Trade names and trademarks 637,500 - 637,500 637,500 Assembled workforce 282,500 (84,750 ) 197,750 211,875 Patents 972,000 (661,685 ) 310,315 336,157 $ 8,496,164 $ (1,181,585 ) $ 7,314,579 $ 7,427,071
Schedule of amortization expense for future periods	Amount 2018 $ 112,492 2019 224,984 2020 224,984 2021 224,984 2022 and thereafter 735,971 Total $ 1,523,415

Plant and Equipment (Tables)

Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Plant and Equipment [Abstract]
Schedule of plant and equipment	June 30, December 31, Cost Amortization and Impairment Net book value Net book value Laboratory equipment $ 2,495,965 $ (1,214,464 ) $ 1,281,501 $ 1,396,617 Computer software 1,671,192 (1,246,969 ) 424,223 716,860 Computer equipment 94,276 (52,337 ) 41,939 43,816 Leasehold improvements 38,974 (22,887 ) 16,087 24,460 $ 4,300,407 $ (2,536,657 ) $ 1,763,750 $ 2,181,753

Other Payable and Accrued Exp35

Other Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2018
Other Payable and Accrued Expenses [Abstract]
Schedule of other payables and accrued expenses	June 30, December 31, Bonus and vacation accrual $ 2,373,987 $ 1,871,488 Payroll liabilities 61,628 44,858 Severance cost accrual 76,355 262,966 Interest accrual 118,768 108,333 Advances from shareholders 300,000 - Other 368,784 152,797 $ 3,299,522 $ 2,440,442

Legal Settlement Liabilities (T

Legal Settlement Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Legal Settlement Liabilities\Commitments and Contingencies [Abstract]
Schedule of legal settlement liabilities	June 30, December 31, Settlement liability accruals Dentons dispute $ - $ 400,000 Eisenschenk matter - 83,333 Other 10,000 10,000 10,000 493,333 Disclosed as follows: Short-term portion 10,000 493,333 $ 10,000 $ 493,333

Deferred Purchase Considerati37

Deferred Purchase Consideration (Tables)	6 Months Ended
	Jun. 30, 2018
Deferred Purchase Consideration [Abstract]
Schedule of deferred purchase consideration	June 30, December 31, Deferred purchase consideration Opening balance $ 9,856,458 $ 10,500,000 Reversal of unearned purchase consideration - (500,000 ) Interest due on deferred purchase consideration 50,978 25,578 Repayment (147,001 ) (169,120 ) Closing balance 9,760,435 9,856,458 Present value discount on future payments Opening balance (1,417,336 ) (1,712,689 ) Imputed interest expense 149,538 300,511 Fair value adjustments - (5,158 ) Closing balance (1,267,798 ) (1,417,336 ) Deferred purchase consideration, net 8,492,636 8,439,122 Disclosed as follows: Short-term portion 200,000 206,458 Interest disclosed under other payables 10,434 - Long-term portion 8,282,202 8,232,664 Deferred purchase consideration, net $ 8,492,636 $ 8,439,122

Loans Payable (Tables)

Loans Payable (Tables)	6 Months Ended
	Jun. 30, 2018
Loans Payable [Abstract]
Schedule of loans payable	June 30, December 31, Asset purchase arrangements $ 99,578 $ 210,690 99,578 210,690 Disclosed as follows: Short-term portion 54,484 139,394 Long-term portion 45,094 71,296 $ 99,578 $ 210,690
Schedule of future principal payments under loans payable	Amount Within 1 year $ 54,484 Within 1 - 2 years 45,094 $ 99,578

Convertible Debt (Tables)

Convertible Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Convertible Debt [Abstract]
Schedule of convertible debt	June 30, December 31, Convertible debt Opening balance $ 10,000,000 $ - Convertible debt issued - 10,000,000 Closing balance 10,000,000 10,000,000 Debt discount Opening balance (4,138,206 ) - Original issue discount - (400,000 ) Fair value of warrants and beneficial conversion feature of notes - (4,518,277 ) Amortization of debt discount 694,010 780,071 Closing balance (3,444,196 ) (4,138,206 ) Convertible debt, net 6,555,804 5,861,794 Disclosed as follows: Short-term portion - - Long-term portion 6,555,804 5,861,794 Convertible debt, net $ 6,555,804 $ 5,861,794

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended
	Jun. 30, 2018
Derivative Liability [Abstract]
Schedule of the following assumptions were used in the Black-Scholes valuation model	Six months ended June 30, 2018 Calculated stock price $ 3.50 Risk free interest rate 2.39 to 2.78% Valuation period 1.88 to 7 years expected volatility of underlying stock 44.6 to 68.0% Expected dividend rate 0%
Schedule of the movement on derivative liability	June 30, December 31, Opening balance $ 4,168,965 $ - Derivative liability on beneficial conversion feature of convertible debt and warrants issued to note holders - 4,518,278 Derivative liability on the fair value of series C Preferred stock warrants issued 1,386,699 - Mark-to-market adjustment 1,045,537 (349,313 ) Closing balance $ 6,601,201 $ 4,168,965

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Warrants [Abstract]
Schedule of warrant activity	No. of Exercise price per share Weighted average exercise Outstanding January 1, 2017 2,147,641 $3.50 to $11.40 $ 3.57 Granted 1,107,143 3.50 3.50 Forfeited/cancelled (75,000 ) 4.20 4.20 Exercised - - - Outstanding December 31, 2017 3,179,784 $3.50 to $4.20 3.50 Granted 599,991 - 3.50 Forfeited/cancelled (75,000 ) 4.20 4.20 Exercised - - - Outstanding June 30, 2018 3,704,775 $3.50 to $4.20 $ 3.51
Schedule of warrants outstanding and exercisable	Warrants outstanding Warrants exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $ 3.50 3,561,374 3.27 3,561,374 $ 3.85 143,401 2.00 143,401 3,704,775 3.22 $ 3.51 3,704,775 $ 3.51

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
	Jun. 30, 2018
Stock Options [Abstract]
Schedule of changes stock option activity	No. of Exercise price per share Weighted average exercise Outstanding January 1, 2017 1,333,291 $0.40 to $11.42 $ 3.59 Granted 120,000 3.50 3.50 Forfeited/cancelled (33,332 ) 3.50 3.50 Exercised - - - Outstanding December 31, 2017 1,419,959 $0.40 to $11.42 3.59 Granted - - Forfeited/cancelled (37,014 ) 3.50 3.50 Exercised - - - Outstanding June 30 , 2018 1,382,945 $0.40 to $11.42 $ 3.59
Schedule of information about stock options outstanding	Options outstanding Options exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $ 0.40 15,000 4.58 15,000 $ 3.00 312,500 5.45 312,500 $ 3.50 902,154 8.17 527,697 $ 4.00 8,791 2.28 8,791 $ 5.00 128,500 3.24 128,500 $ 11.42 16,000 3.92 16,000 1,382,945 6.22 $ 3.59 1,008,488 $ 3.63

Interest Expense (Tables)

Interest Expense (Tables)	6 Months Ended
	Jun. 30, 2018
Interest Expenses [Abstract]
Schedule of interest expense	Three months ended Three months ended Six months ended Six months ended Imputed interest $ (74,769 ) $ (143,205 ) $ (149,538 ) $ (292,517 ) Debt discount (358,625 ) (535,282 ) (694,010 ) (535,282 ) Interest expense (357,816 ) (174,928 ) (706,845 ) (175,267 ) Other (1,423 ) (539 ) (1,813 ) $ (791,210 ) $ (854,838 ) $ (1,550,932 ) $ (1,004,879 )

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2018
Net Loss Per Common Share [Abstract]
Schedule of computation of diluted loss per shares anti-dilutive	Three months and Three months and Stock options 1,382,945 1,453,291 Warrants 3,704,775 3,254,784 Convertible securities 3,457,134 - 8,544,854 4,708,075

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2018
Operating Leases [Abstract]
Schedule of future annual minimum payments required under operating lease obligations	Amount 2018 $ 96,653 2019 66,649 Total $ 163,601

Accounting Policies and Estim46

Accounting Policies and Estimates (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Summary of revenues by major customer type
Total revenues	$ 4,375,969	$ 5,774,547	$ 7,457,118	$ 11,594,497
Services revenue [Member]
Summary of revenues by major customer type
Total revenues	4,375,969	3,179,958	7,457,118	6,473,753
Subsidy revenue [Member]
Summary of revenues by major customer type
Total revenues		2,400,000		4,800,000
Government grants [Member]
Summary of revenues by major customer type
Total revenues		$ 194,589		$ 320,744

Accounting Policies and Estim47

Accounting Policies and Estimates (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)Customer	Jun. 30, 2017USD ($)Customer	Dec. 31, 2017USD ($)
Accounting Policies and Estimates (Textual)
Cash balances insured by FDIC	$ 250,000		$ 250,000
Cash balances uninsured by FDIC	1,233,033		1,233,033
Balance of receivables provision	0		0		$ 0
Bad debt provision	0	$ 0	0	$ 0
Selling, general and administrative expenses	$ 676,583	$ 791,732	$ 1,535,778	$ 1,486,620
Concentration risk, percentage			71.00%	71.30%
Number of customers | Customer			4	3

Going Concern (Details)

Going Concern (Details) - USD ($)	Aug. 13, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Jul. 11, 2018	May 30, 2018	Apr. 04, 2018
Going Concern (Textual)
Net loss		$ (3,500,637)	$ (1,916,274)	$ (7,233,077)	$ (2,722,000)	$ (6,110,434)
Accumulated deficit		(41,050,288)		(41,050,288)		$ (33,757,671)
First tranche [Member]
Going Concern (Textual)
Preferred stock equity									$ 2,100,000
Second tranche [Member]
Going Concern (Textual)
Preferred stock equity								$ 2,100,000
Minimum [Member]
Going Concern (Textual)
Working capital		(180,357)		(180,357)
Maximum [Member]
Going Concern (Textual)
Working capital		$ (2,773,975)		$ (2,773,975)
Subsequent Events [Member]
Going Concern (Textual)
Preferred stock equity							$ 400,000
Tranche description	The first tranche of fifty units of our note and warrant offering of a maximum of one hundred fifty units, each unit consisting of a $10,000 note and a warrant exercisable for 1,500 shares of common stock at an exercise price of $3.50 per share, raising an additional $500,000

Prepaid Expenses and Other Cu49

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 37,072	$ 75,774
Prepaid maintenance	119,511	129,260
Prepaid rent		2,500
Prepaid subscriptions	1,771	5,833
Total	$ 158,354	$ 213,367

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Summary of intangible assets
Cost	$ 8,496,164
Amortization and Impairment	(1,181,585)
Net book value	7,314,579	$ 7,427,071
Cell lines [Member]
Summary of intangible assets
Cost	5,153,664
Amortization and Impairment
Net book value	5,153,664	5,153,664
Discovery platform [Member]
Summary of intangible assets
Cost	1,450,500
Amortization and Impairment	(435,150)
Net book value	1,015,350	1,087,875
Trade names and trademarks [Member]
Summary of intangible assets
Cost	637,500
Amortization and Impairment
Net book value	637,500	637,500
Assembled workforce [Member]
Summary of intangible assets
Cost	282,500
Amortization and Impairment	(84,750)
Net book value	197,750	211,875
Patents [Member]
Summary of intangible assets
Cost	972,000
Amortization and Impairment	(661,685)
Net book value	$ 310,315	$ 336,157

Intangible Assets (Details 1)

Intangible Assets (Details 1)	Jun. 30, 2018USD ($)
Summary of amortization expense for future periods
2,018	$ 112,492
2,019	224,984
2,020	224,984
2,021	224,984
2022 and thereafter	735,971
Total	$ 1,523,415

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Intangible Assets (Textual)
Amortization expense	$ 56,246	$ 56,246	$ 112,492	$ 112,492

Plant and Equipment (Details)

Plant and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Components of plant and equipment
Cost	$ 4,300,407
Amortization and Impairment	(2,536,657)
Net book value	1,763,750	$ 2,181,753
Laboratory equipment [Member]
Components of plant and equipment
Cost	2,495,965
Amortization and Impairment	(1,214,464)
Net book value	1,281,501	1,396,617
Computer equipment [Member]
Components of plant and equipment
Cost	94,276
Amortization and Impairment	(52,337)
Net book value	41,939	43,816
Leasehold improvements [Member]
Components of plant and equipment
Cost	38,974
Amortization and Impairment	(22,887)
Net book value	16,087	24,460
Computer software [Member]
Components of plant and equipment
Cost	1,671,192
Amortization and Impairment	(1,246,969)
Net book value	$ 424,223	$ 716,860

Plant and Equipment (Details Te

Plant and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Plant and Equipment (Textual)
Depreciation expense	$ 368,274	$ 458,174	$ 825,730	$ 842,905

Other Payable and Accrued Exp55

Other Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Current [Abstract]
Bonus and vacation accrual	$ 2,373,987	$ 1,871,488
Payroll liabilities	61,628	44,858
Severance cost accrual	76,355	262,966
Interest accrual	118,768	108,333
Advances from shareholders	300,000
Other	368,784	152,797
Total	$ 3,299,522	$ 2,440,442

Other Payable and Accrued Exp56

Other Payable and Accrued Expenses (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Other Payable and Accrued Expenses (Textual)
Shareholders amount	$ 300,000

Legal Settlement Liabilities (D

Legal Settlement Liabilities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Settlement liability accruals
Settlement liability accruals, gross	$ 10,000	$ 493,333
Disclosed as follows:
Short-term portion	10,000	493,333
Settlement liability accrual	10,000	493,333
Dentons dispute [Member]
Settlement liability accruals
Settlement liability accruals, gross		400,000
Eisenschenk matter [Member]
Settlement liability accruals
Settlement liability accruals, gross		83,333
Other [Member]
Settlement liability accruals
Settlement liability accruals, gross	$ 10,000	$ 10,000

Legal Settlement Liabilities 58

Legal Settlement Liabilities (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Legal Settlement Liabilities (Textual)
Outstanding legal matters	$ 10,000	$ 493,333

Deferred Purchase Considerati59

Deferred Purchase Consideration (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Deferred purchase consideration
Opening balance	$ 9,856,458	$ 10,500,000
Reversal of unearned purchase consideration		(500,000)
Interest due on deferred purchase consideration	50,978	25,578
Repayment	(147,001)	(169,120)
Closing balance	9,760,435	9,856,458
Present value discount on future payments
Opening balance	(1,417,336)	(1,712,689)
Imputed interest expense	149,538	300,511
Fair value adjustments		(5,158)
Closing balance	(1,267,798)	(1,417,336)
Deferred purchase consideration, net	8,492,636	8,439,122
Disclosed as follows:
Short-term portion	200,000	206,458
Interest disclosed under other payables	10,434
Long-term portion	8,282,202	8,232,664
Deferred purchase consideration, net	$ 8,492,636	$ 8,439,122

Deferred Purchase Considerati60

Deferred Purchase Consideration (Details Textual)	6 Months Ended
	Jun. 30, 2018
Deferred Purchase Consideration (Textual)
Deferred purchase consideration, description	In terms of the Icagen asset purchase agreement entered into on July 1, 2015, with a subsidiary of Pfizer, Inc, now known as Pfizer Research (NC), Inc., the Company has the following deferred purchase price obligations: ● commencing May 30, 2017, the Company is obligated to pay additional purchase price consideration calculated (“Earn Out Payment”) at the greater of (i) 10% (ten percent) of gross revenues per quarter (exclusive of revenue paid by Sanofi to Icagen-T) and (ii) $250,000 per quarter up to an aggregate maximum of $10,000,000 (the Maximum Earn Out Payment”), subject to the next paragraph. These earn out payments are payable quarterly, 60 days after the completion of each calendar quarter. There are no indications that the Company will not meet the maximum earn out payment. The Company amended its agreement with Pfizer Research (NC), Inc. (the Second Amendment”), whereby the Company, at its option, may defer payment of any amount exceeding $50,000 of the minimum additional purchase price consideration of $250,000 per quarter until March 31, 2019 such that the Company is only required to pay $50,000 per quarter for the quarters ending March 2017 to December 2018. Deferred purchase consideration bears interest at a rate of 12.5% per annum, which interest is payable quarterly. The deferred purchase consideration in terms of this agreement is payable, together with the deferred purchase consideration for the quarter ended March 31, 2019, as one lump sum. The Second Amendment also provides that if there is an Insolvency Event (as such term is defined in the Second Amendment) prior to the time that Pfizer Research (NC), Inc. has received the Maximum Earn Out Payment, then upon such Insolvency Event, the full amount of any Earn Out Shortfall (the difference between the Maximum Earn Out Payment and the amount of all Earn Out Payments paid to date) shall be due and payable without further notice, demand or presentment for payment. ● The $500,000 deferred purchase consideration due on July 1, 2017, was not earned by Pfizer due to Pfizer not meeting its $4,000,000 revenue target. This liability of $500,000 was reversed as other income during the year ended December 31, 2017.

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Schedule of loans payable
Total	$ 99,578	$ 210,690
Asset purchase arrangements [Member]
Schedule of loans payable
Total	99,578	210,690
Short-term portion [Member]
Schedule of loans payable
Total	54,484	139,394
Long-term portion [Member]
Schedule of loans payable
Total	$ 45,094	$ 71,296

Loans Payable (Details 1)

Loans Payable (Details 1)	Jun. 30, 2018USD ($)
Schedule of future principal payments under loans payable
Within 1 year	$ 54,484
Within 1 - 2 years	45,094
Total principal payments	$ 99,578

Loans Payable (Details Textual)

Loans Payable (Details Textual)	6 Months Ended
	Jun. 30, 2018USD ($)
Purchase Consideration One [Member]
Loans Payable (Textual)
Asset purchase arrangements, description	The Company acquired laboratory equipment on August 11, 2017 for a purchase consideration of $59,320 in terms of a deferred purchase arrangement whereby a deposit of $5,932 was paid and twenty-four monthly installments of $2,472 will be paid commencing on September 11, 2017. The installments bear interest at an effective rate of 10.33% per annum.
Company owed amount	$ 35,208
Purchase Consideration Two [Member]
Loans Payable (Textual)
Asset purchase arrangements, description	The Company acquired laboratory software during September 2017 for a purchase consideration of $98,446 in terms of a deferred purchase arrangement whereby a deposit of $10,546 was paid and the balance payable in thirty five monthly installments of $2,750 each, which commenced on September 30, 2017. The installments bear interest at an effective rate of 6.15% per annum.
Company owed amount	$ 64,370

Convertible Debt (Details)

Convertible Debt (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Convertible debt
Opening balance	$ 10,000,000
Convertible debt issued		10,000,000
Closing balance	10,000,000	10,000,000
Debt discount
Opening balance	(4,138,206)
Original issue discount		(400,000)
Fair value of warrants and beneficial conversion feature of notes		(4,518,277)
Amortization of debt discount	694,010	780,071
Closing balance	(3,444,196)	(4,138,206)
Convertible debt, net	6,555,804	5,861,794
Disclosed as follows:
Short-term portion
Long-term portion	6,555,804	5,861,794
Convertible debt, net	$ 6,555,804	$ 5,861,794

Convertible Debt (Details Textu

Convertible Debt (Details Textual) - USD ($)	May 15, 2017	Apr. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	May 10, 2017
Convertible Debt (Textual)
Repayment of bridge notes				$ 1,500,000
Principal amount					$ 2,000,000
Senior Secured Convertible Note [Member]
Convertible Debt (Textual)
Note percentage rate		8.00%
Maturity date	May 15, 2022
Exercise price of stock	$ 3.50
Note convert, description	A holder of the Purchaser Warrant will not have the right to exercise any portion of the Purchaser Warrant if such holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to its conversion (the "Beneficial Ownership Limitation"). A holder of the Purchaser Warrant may adjust the Beneficial Ownership Limitation upon not less than 61 days' prior notice to the Company, provided that such Beneficial Ownership Limitation in no event shall exceed 9.99%.
Repayment of bridge notes		$ 1,500,000
Accrued but unpaid interest amount		$ 500,000
Warrants exercisable to purchase common stock, shares	857,143
Icagen-T [Member] | Senior Secured Convertible Note [Member]
Convertible Debt (Textual)
Securities purchase agreement, description	(i) the Company issued to the Purchaser a three year Senior Secured Convertible Note ("Company Note"), maturing on May 15, 2020, bearing interest at the rate of 13% per annum (which interest rate increases to 18% per annum upon the occurrence of an event of default, as defined in the Company Note), in the aggregate principal amount of $2,000,000 for cash proceeds of $1,920,000 after an original issue discount of 4% or $80,000, before deal related expenses; and (ii) Icagen-T issued to the Purchaser a three year Senior Secured Convertible Note ("Icagen-T Note"), maturing on May 15, 2020, bearing interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000 for cash proceeds of $7,680,000 after an original issue discount of 4% or $320,000, before transaction related expenses.
Note percentage rate	13.00%
Maturity date	May 15, 2020
Senior secured convertible note, term	3 years
Exercise price of stock	$ 3.50
Note convert, description	The Company and Icagen-T, has the right to redeem all or part of each Convertible Note then outstanding, with a minimum prepayment amount of $500,000, at any time upon five (5) business days' notice to the Purchaser by paying an amount in cash equal to: a range between 101% and 103% of the Conversion Amount being redeemed if paid in full and if an Event of Default has occurred and is continuing the Purchaser has the right to require the Company to redeem the Conversion Amount for an amount of cash equal to a range between 116% and 118% of the Conversion Amount being redeemed. The "Conversion Amount" is defined as the sum of (a) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made, (b) all accrued and unpaid Interest with respect to such portion of such principal, (c) all accrued and unpaid late charges with respect to such portion of such principal and such Interest, if any, and (d) all other amounts due thereunder.
Aggregate gross cash proceeds	$ 1,920,000
Principal amount	$ 2,000,000
Icagen-T Note [Member]
Convertible Debt (Textual)
Principal amount					$ 8,000,000

Derivative Liability (Details)

Derivative Liability (Details)	6 Months Ended
	Jun. 30, 2018$ / shares
Derivative [Line Items]
Calculated stock price	$ 3.50
Expected dividend rate	0.00%
Minimum [Member]
Derivative [Line Items]
Risk free interest rate	2.39%
Valuation period	1 year 10 months 17 days
Expected volatility of underlying stock	44.60%
Maximum [Member]
Derivative [Line Items]
Risk free interest rate	2.78%
Valuation period	7 years
Expected volatility of underlying stock	68.00%

Derivative Liability (Details 1

Derivative Liability (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Derivative Liability [Abstract]
Opening balance	$ 4,168,965
Derivative liability on beneficial conversion feature of convertible debt and warrants issued to note holders		4,518,278
Derivative liability on the fair value of series C Preferred stock warrants issued	1,386,699
Mark-to-market adjustment	(1,045,537)	(349,313)
Closing balance	$ 6,601,201	$ 4,168,965

Derivative Liability (Details T

Derivative Liability (Details Textual)	6 Months Ended
	Jun. 30, 2018USD ($)
Derivative Liability (Textual)
Beneficial conversion feature of convertible debt	$ 3,069,649
Warrants issued in connection with the convertible notes value	1,448,629
Mark-to-market gain	$ 1,045,537
Derivative liability, description	Each Preferred Series C unit includes warrants exercisable over 28,571 shares of common stock at an initial exercise price of $3.50 per share subject to anti-dilution pricing adjustments. The anti-dilution pricing adjustments give rise to a derivative financial liability which was initially valued using a Black Sholes valuation model at $1,386,699.

Series C Preferred Stock (Detai

Series C Preferred Stock (Details) - USD ($)	Apr. 04, 2018	May 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Series C Preferred Stock (Textual)
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Accrued dividends			$ 59,540
First tranche [Member]
Series C Preferred Stock (Textual)
Proceeds from issuance public offering	$ 2,000,000
Second tranche [Member]
Series C Preferred Stock (Textual)
Proceeds from issuance public offering		$ 100,000
Private Placement [Member]
Series C Preferred Stock (Textual)
Preferred stock, cumulative dividend at the rate			12.00%
Stock transaction, description			The Company has offered on a best efforts basis up to a maximum of forty (40) units and a minimum of ten (10) units, at a purchase price of $100,000 per unit, each unit consisting of 28,571 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Preferred Stock") and a seven year Warrant to acquire 28,571 shares of the Company's common stock, par value, $0.001 per share, at an exercise price of $3.50 per share.
Debt conversion, description			(i) closing of a sale of shares of common stock to the public in a Qualifying Public Offering (as defined below) or a reverse merger into a publicly reporting company that has its common stock listed or quoted and traded on a Trading Market (as such term is defined in the Certificate of Designation) or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least seventy-five percent (75%) of the outstanding shares of Series C Preferred Stock (the "Requisite Holders") (the time of such closing or the date and time specified of the event specified in such vote or written consent is referred to herein as the "Mandatory Conversion Date").
Sale of biological assets			Sale of biological assets or other upfront payments, resulting in aggregate gross proceeds received by us at closing or closings in a transaction or transactions during any twelve (12) month period in excess of $40,000,000.
Series C Preferred Stock [Member]
Series C Preferred Stock (Textual)
Preferred stock, shares authorized			1,142,856	1,142,856
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares issued			599,991
Preferred stock, shares outstanding			599,991
Series C Preferred Stock [Member] | Private Placement [Member]
Series C Preferred Stock (Textual)
Liquidity event, description			In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series C Preferred Stock shall be entitled to a preference on liquidation equal to $5.25 per share of Series C Preferred Stock plus all accrued and unpaid dividends.

Common Stock (Details)

Common Stock (Details) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Common Stock (Textual)
Common stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	6,720,107	6,720,107
Common stock, shares outstanding	6,393,107	6,393,107

Warrants (Details)

Warrants (Details) - Warrants [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Schedule of warrant activity
Number of shares, Outstanding, Beginning balance	3,179,784	2,147,641
Number of shares, Granted	599,991	1,107,143
Number of shares, Forfeited/cancelled	(75,000)	(75,000)
Number of shares, Exercised
Number of shares, Outstanding, Ending balance	3,704,775	3,179,784
Exercise price per share, Granted		$ 3.50
Exercise price per share, Forfeited/cancelled	4.20	4.20
Exercise price per share, Exercised
Weighted average exercise price, Beginning Balance	3.50	3.57
Weighted average exercise price, Granted	3.50	3.50
Weighted average exercise price, Forfeited/cancelled	4.20	4.20
Weighted average exercise price, Exercised
Weighted average exercise price, Ending Balance	3.51	3.50
Minimum [Member]
Schedule of warrant activity
Exercise price per share, Beginning balance	3.50	3.50
Exercise price per share, Ending balance	3.50	3.50
Maximum [Member]
Schedule of warrant activity
Exercise price per share, Beginning balance	4.20	11.40
Exercise price per share, Ending balance	$ 4.20	$ 4.20

Warrants (Details 1)

Warrants (Details 1) - Warrants [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of warrants outstanding and exercisable
Warrants outstanding, Number of shares	3,704,775	3,179,784	2,147,641
Warrants outstanding, Weighted average remaining years	3 years 2 months 19 days
Warrants outstanding, Weighted average exercise price	$ 3.51	$ 3.50	$ 3.57
Warrants exercisable, Number of shares	3,704,775
Warrants exercisable, Weighted average exercise price	$ 3.51
$3.50 [Member]
Schedule of warrants outstanding and exercisable
Exercise price	$ 3.50
Warrants outstanding, Number of shares	3,561,374
Warrants outstanding, Weighted average remaining years	3 years 3 months 8 days
Warrants exercisable, Number of shares	3,561,374
$3.85 [Member]
Schedule of warrants outstanding and exercisable
Exercise price	$ 3.85
Warrants outstanding, Number of shares	143,401
Warrants outstanding, Weighted average remaining years	2 years
Warrants exercisable, Number of shares	143,401

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	Apr. 04, 2018	May 30, 2018	Jun. 30, 2018
Warrants (Textual)
Warrant beneficial ownership limitation, description			In addition, subject to limited exceptions, a holder of the Warrant will not have the right to exercise any portion of the Warrant if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to such exercise. A holder of the Warrant may adjust this limitation upon not less than 61 days' prior notice to the Company, provided that such limitation in no event shall exceed 9.99%.
Initial exercise price of warrant			$ 3.50
Warrants exercisable, description			Each unit consisting of 28,571 shares of Series C Preferred Stock and warrants exercisable over 28,571 shares of common stock. The Warrant expires seven years after the issuance date.
First tranche [Member]
Warrants (Textual)
Initial exercise price of warrant	$ 3.50
Proceeds from Issuance Initial Public Offering	$ 2,000,000
Warrants exercisable	571,420
Second tranche [Member]
Warrants (Textual)
Initial exercise price of warrant		$ 3.50
Proceeds from Issuance Initial Public Offering		$ 100,000
Warrants exercisable		28,571

Stock Options (Details)

Stock Options (Details) - Option [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Summary of changes in options outstanding
Number of shares, Outstanding, Beginning balance	1,402,945	1,333,291
Number of shares, Granted		120,000
Number of shares, Forfeited/cancelled	(37,014)	(33,332)
Number of shares, Exercised
Number of shares, Outstanding, Ending balance	1,382,945	1,402,945
Exercise price per share, Granted		$ 3.50
Exercise price per share Forfeited/cancelled	3.50	3.50
Exercise price per share, Exercised
Weighted average exercise price, Beginning Balance	3.59	3.59
Weighted Average Exercise Price, Granted		3.50
Weighted Average Exercise Price, Forfeited/cancelled	3.50	3.50
Weighted Average Exercise Price, Exercised
Weighted average exercise price, Ending Balance	3.59	3.59
Minimum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance	0.40	0.40
Exercise price per share, Ending balance	0.40	0.40
Maximum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance	11.42	11.42
Exercise price per share, Ending balance	$ 11.42	$ 11.42

Stock Options (Details 1)

Stock Options (Details 1) - Stock Options [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary of information about stock options outstanding
Options outstanding, Number of shares	1,382,945	1,402,945	1,333,291
Options outstanding, Weighted average remaining years	6 years 2 months 19 days
Options outstanding, Weighted average exercise price	$ 3.59	$ 3.59	$ 3.59
Options exercisable, Number of shares	1,008,488
Options exercisable, Weighted average exercise price	$ 3.63
$0.40 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 0.40
Options outstanding, Number of shares	15,000
Options outstanding, Weighted average remaining years	4 years 6 months 29 days
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	15,000
Options exercisable, Weighted average exercise price
$3.00 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 3
Options outstanding, Number of shares	312,500
Options outstanding, Weighted average remaining years	5 years 5 months 12 days
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	312,500
Options exercisable, Weighted average exercise price
$3.50 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 3.50
Options outstanding, Number of shares	902,154
Options outstanding, Weighted average remaining years	8 years 2 months 1 day
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	527,697
Options exercisable, Weighted average exercise price
$4.00 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 4
Options outstanding, Number of shares	8,791
Options outstanding, Weighted average remaining years	2 years 3 months 11 days
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	8,791
Options exercisable, Weighted average exercise price
$5.00 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 5
Options outstanding, Number of shares	128,500
Options outstanding, Weighted average remaining years	3 years 2 months 27 days
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	128,500
Options exercisable, Weighted average exercise price
$11.42 [Member]
Summary of information about stock options outstanding
Exercise Price	$ 11.42
Options outstanding, Number of shares	16,000
Options outstanding, Weighted average remaining years	3 years 11 months 1 day
Options outstanding, Weighted average exercise price
Options exercisable, Number of shares	16,000
Options exercisable, Weighted average exercise price

Stock Options (Details Textual)

Stock Options (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock Options (Textual)
Unvested options to purchase common stock	374,457		374,457
Total expected unrecognized compensation cost	$ 791,156		$ 791,156
Expected recognized period			36 months
Stock option based compensation expense	151,712	$ 165,282	$ 305,620	$ 315,192
Stock options outstanding, intrinsic value	$ 202,750		$ 202,750

Interest Expense (Details)

Interest Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Interest Expenses [Abstract]
Imputed interest	$ (74,769)	$ (143,205)	$ (149,538)	$ (292,517)
Debt discount	(358,625)	(535,282)	(694,010)	(535,282)
Interest expense	(357,816)	(174,928)	(706,845)	(175,267)
Other		(1,423)	(539)	(1,813)
Interest expense	$ (791,210)	$ (854,838)	$ (1,550,932)	$ (1,004,879)

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Summary of dilutive shares exercise of outstanding stock instruments
Anti dilutive shares pursuant to the exercise of outstanding stock instruments	8,544,854	4,708,075	8,544,854	4,708,075
Convertible securities [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti dilutive shares pursuant to the exercise of outstanding stock instruments	3,457,134		3,457,134
Stock options [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti dilutive shares pursuant to the exercise of outstanding stock instruments	1,382,945	1,453,291	1,382,945	1,453,291
Warrants [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti dilutive shares pursuant to the exercise of outstanding stock instruments	3,704,775	3,254,784	3,704,775	3,254,784

Related Party Transaction (Deta

Related Party Transaction (Details) - USD ($)	Apr. 04, 2018	May 30, 2018
Timothy Tyson [Member]
Related Party Transaction (Textual)
Related party transaction, description	The Company entered into a Securities Purchase Agreement whereby Mr. Tyson acquired twenty (20) Series C Preferred Stock units for $100,000 each, each unit consisting of 28,571 Series C Preferred shares and a seven year warrant exercisable over 28,571 shares of common stock, at an exercise price of $3.50 per share. Mr. Tyson acquired a total of 571,420 Series C Preferred shares and warrants exercisable over 571,420 shares of common stock.
Clive Kabatznik [Member]
Related Party Transaction (Textual)
Related party transaction, description		The Company entered into a Securities Purchase Agreement whereby Mr. Kabatznik acquired one (1) Series C Preferred Stock unit for $100,000 each, each unit consisting of 28,571 Series C Preferred shares and a seven year warrant exercisable over 28,571 shares of common stock, at an exercise price of $3.50 per share. Mr. Kabatznik acquired a total of 28,571 Series C Preferred shares and warrants exercisable over 28,571 shares of common stock.
Michael Taglich [Member]
Related Party Transaction (Textual)
Advance payable		$ 150,000
Robert Taglich [Member]
Related Party Transaction (Textual)
Advance payable		$ 150,000

Operating Leases (Details)

Operating Leases (Details)	Jun. 30, 2018USD ($)
Summary of future annual minimum payments required under operating lease obligations
2,018	$ 96,653
2,019	66,649
Total	$ 163,601

Operating Leases (Details Textu

Operating Leases (Details Textual)	6 Months Ended
	Jun. 30, 2018USD ($)
Operating Leases (Textual)
Rental expense	$ 98,915
Lease expiration date	Apr. 30, 2019

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	May 15, 2017	Jun. 19, 2017	Jun. 30, 2018
Commitments and Contingencies (Textual)
Commitments, description	(i) the Company issued to the Purchaser the Company Note which is a three year Senior Secured Convertible Note, maturing on May 15, 2020, bearing interest at the rate of 13% per annum (which interest rate increases to 18% per annum upon the occurrence of an event of default, as defined in the Note), in the aggregate principal amount of $2,000,000 for cash proceeds of $1,920,000 after an original issue discount of 4% or $80,000, before deal related expenses; and (ii) Icagen-T issued to the Purchaser the Icagen-T note which is a three year Senior Secured Convertible Note, maturing on May 15, 2020, bearing interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000 for cash proceeds of $7,680,000 after an original issue discount of 4% or $320,000, before deal related expenses. The Company Note and the Icagen-T Note are each convertible into shares of common stock at a conversion price of $3.50 per share.		(i) to continue to retain certain employees at its Icagen-T facility until July 15, 2018, which it estimates will require additional compensation of $400,000 at its Icagen-T facility; (ii) make additional payments in terms of the Asset Purchase and Collaboration Agreement that it entered into on June 26, 2015 with Pfizer including beginning in 2017, a quarterly earn out payment (the "Earn Out Payment") of 10% of revenue earned during the quarter, with a minimum payment of $250,000 per quarter, up to a maximum aggregate payment of $10,000,000, such minimum being reduced to $50,000 for the quarters ending March 2017 to December 2018 and the difference between $250,000 or the quarterly amount paid and the actual calculation of deferred purchase consideration at 10% of gross revenue per quarter is being deferred and paid as one lump sum with the payment being made the quarter ended March 31, 2019, bearing interest at 12.5% per annum, which interest is payable quarterly; (iii) make minimum lease payments in terms of a sub-lease agreement entered into with Pfizer for the period July l, 2015 to April 30, 2019 with annual escalations of 3.5%, estimated to be $163,601.
Annual base salary		$ 285,000
Performance bonus payment percentage		35.00%
Employee agreement term		4 years

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jul. 13, 2018	Aug. 23, 2018	Jun. 30, 2018	May 10, 2017
Subsequent Events (Textual)
Exercise Price			$ 3.50
Principal amount				$ 2,000,000
Private Placement [Member]
Subsequent Events (Textual)
Stock transaction, description			The Company has offered on a best efforts basis up to a maximum of forty (40) units and a minimum of ten (10) units, at a purchase price of $100,000 per unit, each unit consisting of 28,571 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Preferred Stock") and a seven year Warrant to acquire 28,571 shares of the Company's common stock, par value, $0.001 per share, at an exercise price of $3.50 per share.
Icagen-T Note [Member]
Subsequent Events (Textual)
Principal amount				$ 8,000,000
Subsequent Events [Member]
Subsequent Events (Textual)
Warrants to purchase of shares		1,500
Warrants to purchase share value		$ 10,000
Warrants term		5 years
Exercise Price		$ 3.50
Principal amount		$ 10,000
Description of warrants		Pursuant to which the Company issued to the Purchasers an aggregate of fifty (50) units, at a purchase price of $10,000 per unit, each unit consisting of: (i) the Company’s 10% Subordinated Promissory Note in the principal amount of $10,000 due on the earlier of: (x) the date that is twelve (12) months after its issue date or (y) the Company’s receipt of the proceeds of funding from its next collaboration/partnership (the “Note”) and (ii) a five year warrant to purchase 1,500 shares of common stock of the Company for each $10,000 Note investment of the Company at an exercise price of $3.50 per share (the “Warrant”). An aggregate of $500,000 in principal amount of Notes and Warrants to purchase an aggregate of 75,000 shares of common stock were sold at the closing. The gross cash proceeds to the Company from the sale of the fifty (50) units was $500,000.
Subsequent Events [Member] | Private Placement [Member]
Subsequent Events (Textual)
Proceeds from issuance public offering	$ 400,000